
American Association for Cancer Research
- AbstractMelanocytes reside in diverse microenvironments that influence their susceptibility to oncogenic transformation; however, investigation of rare melanoma subsets has been limited by the lack of suitable preclinical animal models. In this study, we developed a primary, immunocompetent zebrafish model to study uveal melanoma using choroidal melanocyte–targeted injection and electroporation of plasmids encoding human GNAQQ209L together […]
- AbstractSETD2 is frequently mutated or deleted in clear cell renal cell carcinoma (ccRCC). Loss of SETD2 could create synthetic lethal dependencies that confer therapeutic vulnerabilities. In this study, we demonstrated that SETD2 deficiency promotes cytoplasmic mitochondrial DNA (mtDNA) leakage, leading to basal activation of cGAS-STING inflammatory signaling and increased apoptotic priming. This inflammatory state upregulated […]
- AbstractChimeric antigen receptor (CAR) T-cell therapy has shown early promise against glioblastoma, which lacks effective treatment options. However, two key challenges curtail efficacy: tumor-antigen heterogeneity and an immunosuppressive tumor microenvironment. CAR T cells engineered to secrete combinations of immunomodulatory proteins can reverse immune suppression and engage endogenous immunity. Through head-to-head in vivo comparisons of potentially […]
- AbstractMicrosatellite stable (MSS) rectal cancer exhibits intrinsic resistance to immunotherapy. Although radiotherapy is frequently combined with immune checkpoint inhibitors (ICI) to augment immunotherapy responses, numerous immunologically cold tumors remain unresponsive. In this study, we observed a significant increase in electron transport chain activity, acetyl-CoA levels, and global lysine acetylation levels in patients achieving a pathologic […]
- AbstractGlucocorticoid receptor (GR) signaling is critical to our physiology but is dysregulated in cancer by the pain, psychologic distress, iatrogenic morbidity, and pathology associated with an advanced, invasive disease. Many tumors exploit glucocorticoid signaling to provide antiapoptotic survival signals, stimulate growth and metastasis, suppress immune surveillance, and drive treatment resistance. Endogenous cortisol and exogenous glucocorticoids […]
- AbstractPurpose:The anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, ipilimumab (IPI), has shown clinical benefit across multiple tumor types, both as monotherapy and in combination with nivolumab or chemotherapy. However, not all tumors respond, and peripheral effects can lead to immune-related adverse events. We characterized three novel anti–CTLA-4 antibodies: peptide-masked [PROBODY conditionally activatable therapeutic (PB)], non-fucosylated […]
- AbstractPurpose:Patients with endometrial cancer who progress after chemotherapy/immunotherapy have limited treatment options. We evaluated the activity and safety of sacituzumab govitecan (SG), a Trop-2–directed antibody–drug conjugate, in patients with advanced/recurrent endometrial cancer, including carcinosarcoma.Patients and Methods:This was a phase II, two-stage, open-label, investigator-initiated trial of patients with persistent/recurrent endometrial cancer who had progressed following ≥1 […]
- Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II TrialAbstractPurpose:Eosinophil-related cutaneous adverse events (ercAE) are common after systemic cancer therapies and often affect health-related quality of life (HRQoL). In this study, we investigate the efficacy and safety of benralizumab for ercAE following systemic cancer therapies.Patients and Methods:This single-arm, single-center, open-label, phase II trial (NCT04552288) in patients with cancer and systemic therapy-associated ercAE was performed […]
- AbstractPurpose:Aberrant enhancer dynamics play a critical role in the initiation and progression of colorectal cancer, particularly in the BRAFV600E-mutated metastatic subtype, which uniquely exhibits a strong epigenetic phenotype. Building on this epigenetic vulnerability, bromodomain 2, a reader of H3K27ac-marked enhancers, was found to be synthetically lethal with BRAF + EGFR inhibition.Experimental Design:We evaluated the effectiveness […]
- AbstractPurpose:BI 1701963 is a small-molecule son of sevenless 1 (SOS1) inhibitor that selectively binds to SOS1, blocking the protein–protein interaction of SOS1 with guanosine diphosphate-bound rat sarcoma virus (RAS) proteins [Kirsten RAS (KRAS), Harvey RAS, and neuroblastoma RAS], thereby inhibiting the growth of RAS-dependent cancer cells.Patients and Methods:Three phase I dose-escalation studies evaluated BI 1701963 […]
Cancer.gov
- In a new National Institutes of Health (NIH)-funded study, scientists at Cleveland Clinic discovered that hormones associated with male development may play a key role in limiting the growth of brain tumors in men. The research team found that the loss of androgen hormones, such as testosterone, in a preclinical model of glioblastoma drove tumor […]
- In a National Institutes of Health (NIH)-funded study, researchers developed a cancer assessment tool that can identify high-risk patients and the tumor cells linked to that risk. The model, called scSurvival, uses a machine learning framework designed to analyze large-scale data at single-cell resolution.
- In a new study, funded in part by the National Institutes of Health (NIH), researchers have uncovered a molecular mechanism that could explain how chronic gut inflammation may increase the risk of colorectal cancer. By simulating chronic colitis in mice and tracking the colon’s response during inflammation and recovery, scientists demonstrated that these changes increased […]
- National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical […]
- Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, the findings, published Dec. 10, 2025, in Nature, describe a previously unknown origin of some aggressive lung cancers.
JAMA Oncology – Current Issue
- This randomized clinical trial examines whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in gastric cancer with peritoneal metastasis.
- This Viewpoint discusses concerns with the current grading of cutaneous toxic effects in Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 and proposes an updated framework.
- This cohort study investigates tumor-infiltrating clonal hematopoiesis in solid tumors and evaluates its association with clinical factors and overall survival.
- The Original Investigation titled “PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis,” published online on June 4, 2026, included errors in a data point in Figure 1 and citations in Figures 1 and 3. In Figure 1A, the upper bound of the 95% CI for the […]
- This essay discusses the author’s experience as a physician in Beirut during wartime.
ClinicalTrials.gov – Cancer
- Conditions: Polycystic Ovary Syndrome Interventions: Drug: Orlistat; Drug: Placebo; Behavioral: Standard Lifestyle Advice Sponsors: Khyber Medical University Peshawar Recruiting
- Conditions: Non-Small Cell Lung Cancer; Adjuvant Therapy; Immune Checkpoint Inhibitors Interventions: Drug: Sintilimab Sponsors: Sichuan University Recruiting
- Conditions: Colorectal Neoplasms; Breast Neoplasms Interventions: Behavioral: Chi gung: Stay Well, Live Well; Behavioral: Chi gung: Stay Well, Live Well Sponsors: Icahn School of Medicine at Mount Sinai; National Cancer Institute (NCI) Not yet recruiting
- Conditions: Nsclc; NSCLC Stage II; NSCLC, Stage III; NSCLC Stage IIIB; Resectable Lung Non-Small Cell Carcinoma Interventions: Drug: Cemiplimab Sponsors: University of Maryland, Baltimore; Regeneron Pharmaceuticals Not yet recruiting
- Conditions: Hepatocellular Carcinoma (HCC) Interventions: Procedure: No-touch Microwave Ablation; Procedure: Tumor-puncture Microwave Ablation; Procedure: Surgical Resection Sponsors: The First Hospital of Jilin University Not yet recruiting
STAT!Ref Evidence Alerts
- J Clin Oncol. 2026 Jul 2:JCO2502735. doi: 10.1200/JCO-25-02735.
- Lancet Oncol. 2026 Jul 13:S1470-2045(26)00133-6. doi: 10.1016/S1470-2045(26)00133-6.
- Lancet Oncol. 2026 Jul;27(7):864-878. doi: 10.1016/S1470-2045(26)00235-4.
- JAMA. 2026 Jul 12. doi: 10.1001/jama.2026.10676.
- J Clin Oncol. 2026 May 16:101200JCO2502856. doi: 10.1200/JCO-25-02856.

ACCEL – Professional Insight, always within reach.
Professional Development Insights are part of the Salinas Valley Health’s Medical Staff Services and for our Physicians/APPs, we offer ACCEL.
ACCEL is a professional development platform created exclusively for Physicians and APPs at Salinas Valley Health. It offers expert-led content on the non-clinical aspects of medical practice — the things that shape daily work but rarely fit into formal training. Articles, Book Summaries, Videos, Audio/Visual… just for you!
- Provided at no cost to Medical Staff members
- Optional and self-directed
- Private — not tracked or reported
- Available on any computer or mobile device
- Login and password provided by Medical Staff Services
Here are the Just In insights…
*For providers of Salinas Valley Health, if you need access to any particular article referred to in these news feeds, please email Library@SalinasValleyHealth.com

